Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

被引：0
|
作者：
Kilickap, S. [1 ]
Sezer, A. [2 ]
Gumus, M. [3 ]
Bondarenko, I. [4 ]
Ozguroglu, M. [5 ]
Gogishvili, M. [6 ]
He, X. [7 ]
Gullo, G. [7 ]
Rietschel, P. [7 ]
Quek, R. G. [7 ]
机构：
[1] Istinye Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey
[2] Baskent Univ, Dept Med Oncol, Adana, Turkey
[3] Istanbul Medeniyet Univ, Sch Med, Dept Med Oncol, Istanbul, Turkey
[4] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine
[5] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Istanbul, Turkey
[6] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, Georgia
[7] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
non-small cell lung cancer; patient-reported outcomes; cemiplimab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.15-12
引用
收藏
页码：S125 / S126
页数：2
相关论文
共 50 条
  • [1] Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1
    Ho, G. F.
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G.
    ANNALS OF ONCOLOGY, 2022, 33 : S1573 - S1573
  • [2] Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1089 - S1089
  • [3] Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI plus CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
    Gogishvili, M.
    Melkadze, T.
    Baramidze, A.
    Makharadze, T.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G. W.
    ANNALS OF ONCOLOGY, 2023, 34
  • [4] EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study
    Rizvi, N.
    Lee, S.
    Curtis, P.
    Caldwell, W.
    Gao, B.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S931 - S931
  • [5] Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study
    Gumus, Mahmut
    Chen, Chieh-, I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri J. S.
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    CANCER, 2023, 129 (01) : 118 - 129
  • [6] Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1
    Kilickap, S.
    Sezer, A.
    Ozguroglu, M.
    Gumus, M.
    Bondarenko, I.
    Gogishvili, M.
    Nechaeva, M.
    Schenker, M.
    Cicin, I.
    Fuang, H. G.
    Kulyaba, Y.
    Zyuhal, K.
    Scheusan, R. I.
    Baramidze, A.
    Garassino, M. C.
    Li, Y.
    Jia, X.
    Kaul, M.
    Perez, J.
    Seebach, F.
    Lowy, I.
    Pouliot, J. F.
    Kim, E.
    Rietschel, P.
    Magnan, H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S35 - S35
  • [7] Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
    Baramidze, A.
    Makharadze, T.
    Gogishvili, M.
    Melkadze, T.
    Giorgadze, D.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    McIntyre, D.
    Kaul, M.
    Quek, R. G. W.
    Pouliot, J-F.
    Seebach, F.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2023, 34
  • [8] Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression plus Chemotherapy: EMPOWER-Lung 1
    Garassino, M. C.
    Kilickap, S.
    Ozguroglu, M.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Gogishvili, M.
    Nechaeva, M.
    Schenker, M.
    Cicin, I.
    Fuang, H. G.
    Kulyaba, Y.
    Dvorkin, M.
    Zyuhal, K.
    Scheusan, R. -I.
    He, X.
    Kaul, M.
    Okoye, E.
    Li, Y.
    Li, S.
    Pouliot, J. -F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E2 - E3
  • [9] Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1
    Gumus, M.
    Kilickap, S.
    Sezer, A.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S321 - S321
  • [10] Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.
    Gumus, Mahmut
    Chen, Chieh-I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345